EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced today that it will webcast a post-ASCO analyst briefing on Thursday, June 8, 2006, beginning at 4:30 p.m. Eastern Time. Clinical investigators and management will participate in the event.
The physicians will review recently reported clinical data for Nexavar(R) (sorafenib) tablets, being developed in collaboration with Bayer Pharmaceuticals Corporation. Interested parties may access a live webcast of the presentation by clicking on the link below: http://phx.corporate-ir.net/phoenix.zhtml?p=irol- eventDetails&c=112065&eventID=1318003 or by dialing 617-213-8063 and using the passcode 71300692. A replay of the presentation will be available on the Onyx website through July 8, 2006.
Onyx Pharmaceuticals is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including Nexavar(R) (sorafenib) tablets with Bayer Pharmaceuticals Corporation. For more information about Onyx’s pipeline and activities, visit the company’s website at www.onyx-pharm.com.
NOTE: Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.
Onyx Pharmaceuticals, Inc.
CONTACT: Alex Santos of Onyx Pharmaceuticals, +1-510-597-6504
Web site: http://www.onyx-pharm.com//
